U.S. Markets closed

Tekmira Up 4% On Positive Ebola-Related Drug Study

John Seward

Tekmira Pharmaceuticals (NASDAQ: TKMR) shares gained more than four percent after it was reported that one of its drugs showed promising results in animal studies directed at treating Ebola virus disease.

A peer-reviewed study published Wednesday found that Tekmira's lipid nanoparticle provided "complete protection" in monkeys against Marburg virus infection, the symptoms of which are indistinguishable from Ebola.

The drug appeared effective even when administered up to three days following exposure to the virus, which is closely related to Ebola, the company said.

Related Link: Time To Take Another Look At Tekmira

Results in the journal Science Translational Medicine, were trumpeted in a company press release at 2 p.m. Wednesday and later reported, including in the print edition of Thursday's New York Times.

Tekmira's similar development drug, called TKM-Ebola, got a boost August 7 when regulators modified a clinical hold on the drug to a modified hold, potentially clearing the way for human trials.

Regulators halted a Phase I study of TKM-Ebola on July 3 over safety concerns.

Tekmira traded recently at $18.51, up 4.4 percent.

See more from Benzinga

© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.